Phage-directed precision microbiome medicine: engineering pathobiont depletion, synbiotic succession, microbial-function editing, metabolite host signaling, neurophagomics, and durable ecological state control in gut dysbiosis associated diseases
4 affiliations
- 1Korea University College of Health Sciences, Korea University
- 2Institute of Graduate Studies and Research, Cyprus International University
- 3Széchenyi István University
- 4Center for Research Development, University of Cyberjaya, Persiaran Bestari, Cyberjaya
Abstract
Bacteriophages are being investigated as strain-selective tools for modifying intestinal microbial communities, but the evidence supporting ecological reconstruction is substantially less mature than the evidence supporting targeted bacterial depletion. This review separates current knowledge into three domains: established and emerging experimental evidence, human translational evidence, and hypotheses proposed for future testing. Human studies show that orally administered natural or engineered phages can be recovered from the gastrointestinal tract and can alter selected bacterial populations without antibiotic-like loss of overall community diversity. Preclinical studies further demonstrate targeted suppression of inflammatory Klebsiella pneumoniae in inflammatory bowel disease models, cytolytic Enterococcus faecalis in alcohol-associated liver disease, evolutionary steering of Escherichia coli , in situ bacterial genome editing, local therapeutic-protein production, and phage-probiotic cooperation. These findings do not yet establish that an integrated phage-successor-prebiotic sequence can durably reprogram a human gut ecosystem. To organize this translational gap, we use Subtract-Seed-Feed-Lock as an explicitly proposed design framework. A phage or phage-derived platform first depletes, weakens, or edits a disease-relevant bacterial strain or function; a niche-matched successor is then introduced; a selectively utilized nutrient supports that successor; and durability is assessed after treatment withdrawal. Related terms used in this review—Functional Phageability, Minimum Ecological Dose, Ecological Vacancy Window, nutrient-conditioned phagogram, ecological pharmacokinetics/pharmacodynamics (Eco-PK/PD), ecological pharmacovigilance, neurophagomic reverse translation, and microbiome-state digital twin—are hypothesis-generating operational concepts rather than validated clinical methods. Host signaling is likewise framed as predominantly indirect: phage-induced changes in bacterial abundance or function may alter lipopolysaccharide, short-chain fatty acids, indoles, bile acids, and other metabolites that subsequently engage inflammatory, barrier, hepatic, or neural pathways. The gut-brain application remains especially preliminary; targeting urdA -positive imidazole-propionate producers has not been validated with therapeutic phages. Clinical development will require reproducible good manufacturing practice, control of endotoxin and host-cell contaminants, product stability, resistance and immune-neutralization monitoring, environmental-shedding assessment, and regulatory strategies for genetically modified, dynamically updated, and multi-component products. The immediate opportunity is therefore precise microbial perturbation with evidence-matched endpoints; durable programmed reconstruction remains an experimentally testable objective.
Related
- Root Exudate Metabolite Signatures Drive Microbial Succession and Saline–Alkali Soil Recovery During Long-Term Phytoremediation by Elaeagnus angustifolia L.
- Decoupled recovery of soil physicochemistry, microbiome and methane sink function during secondary forest succession in the Eastern Himalayas
- A strong-to-weak interaction shift during microbiome succession is coupled to colonizer-dependent antimicrobial resistance
- Organic-acid-derived feather hydrolysate drives soil microbiome succession toward copiotrophic and putatively plant-beneficial taxa
- A microbiome-derived metabolite from Staphylococcus epidermidis inhibits Staphylococcus aureus biofilm formation and virulence
BibTeX
@article{saeed2026phagedirected,
title = {{Phage-directed precision microbiome medicine: engineering pathobiont depletion, synbiotic succession, microbial-function editing, metabolite host signaling, neurophagomics, and durable ecological state control in gut dysbiosis associated diseases}},
author = {Umar Saeed and Zahra Zahid Piracha},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1964616},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1964616/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Phage-directed precision microbiome medicine: engineering pathobiont depletion, synbiotic succession, microbial-function editing, metabolite host signaling, neurophagomics, and durable ecological state control in gut dysbiosis associated diseases
AU - Umar Saeed
AU - Zahra Zahid Piracha
PY - 2026
DA - 2026/10/22
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1964616
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1964616/full
AB - Bacteriophages are being investigated as strain-selective tools for modifying intestinal microbial communities, but the evidence supporting ecological reconstruction is substantially less mature than the evidence supporting targeted bacterial depletion. This review separates current knowledge into three domains: established and emerging experimental evidence, human translational evidence, and hypotheses proposed for future testing. Human studies show that orally administered natural or engineered phages can be recovered from the gastrointestinal tract and can alter selected bacterial populations without antibiotic-like loss of overall community diversity. Preclinical studies further demonstrate targeted suppression of inflammatory Klebsiella pneumoniae in inflammatory bowel disease models, cytolytic Enterococcus faecalis in alcohol-associated liver disease, evolutionary steering of Escherichia coli , in situ bacterial genome editing, local therapeutic-protein production, and phage-probiotic cooperation. These findings do not yet establish that an integrated phage-successor-prebiotic sequence can durably reprogram a human gut ecosystem. To organize this translational gap, we use Subtract-Seed-Feed-Lock as an explicitly proposed design framework. A phage or phage-derived platform first depletes, weakens, or edits a disease-relevant bacterial strain or function; a niche-matched successor is then introduced; a selectively utilized nutrient supports that successor; and durability is assessed after treatment withdrawal. Related terms used in this review—Functional Phageability, Minimum Ecological Dose, Ecological Vacancy Window, nutrient-conditioned phagogram, ecological pharmacokinetics/pharmacodynamics (Eco-PK/PD), ecological pharmacovigilance, neurophagomic reverse translation, and microbiome-state digital twin—are hypothesis-generating operational concepts rather than validated clinical methods. Host signaling is likewise framed as predominantly indirect: phage-induced changes in bacterial abundance or function may alter lipopolysaccharide, short-chain fatty acids, indoles, bile acids, and other metabolites that subsequently engage inflammatory, barrier, hepatic, or neural pathways. The gut-brain application remains especially preliminary; targeting urdA -positive imidazole-propionate producers has not been validated with therapeutic phages. Clinical development will require reproducible good manufacturing practice, control of endotoxin and host-cell contaminants, product stability, resistance and immune-neutralization monitoring, environmental-shedding assessment, and regulatory strategies for genetically modified, dynamically updated, and multi-component products. The immediate opportunity is therefore precise microbial perturbation with evidence-matched endpoints; durable programmed reconstruction remains an experimentally testable objective.
SN - 1664-302X
ER -